ArticleRisk management and healthcare policy2025
Cost-Effectiveness of First-Line Zuberitamab-CHOP versus Rituximab-CHOP Regimens in Untreated CD20+ Diffuse Large B-Cell Lymphoma in China.
Lihong Gao et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.